NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate

Cancer Letters

Volumn 344, Issue 2, 2014, Pages 291-298

  Gobin, Bérengère ^a,b   Battaglia, Séverine ^a,b   Lanel, Rachel ^a,b   Chesneau, Julie ^a,b   Amiaud, JérÔme ^a,b   Rédini, Françoise ^a,b,c   Ory, Benjamin ^a,b   Heymann, Dominique ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

MTOR Inhibitor; Osteosarcoma; PI3K Inhibitor; Pre clinical model; Survival rate

Indexed keywords

CASPASE; DACTOLISIB; KI 67 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VASCULARIZATION;

MURINAE; MUS;

MTOR INHIBITOR; OSTEOSARCOMA; PI3K INHIBITOR; PRE-CLINICAL MODEL; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; RANDOM ALLOCATION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893659377     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.11.017     Document Type: Article

References (41)

1. Heymann D., Rédini F. Bone sarcomas: pathogenesis and new therapeutic approaches. BoneKey Rep. 2011, 8:402-414.
2. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J. Rare Dis. 2007, 2:6.
3. Ando K., Heymann M.F., Stresing V., Mori K., Redini F., Heymann D. Current therapeutic strategy and novel approaches in osteosarcoma. Cancers 2013, 5:591-616.
4. Rosen G., Murphy M.L., Huvos A.G., Gutierrez M., Marcove R.C. Chemotherapy, en bloc resection, and prosthetic bone replacement in treatment of osteogenic sarcoma. Cancer 1976, 37:1-11.
5. Link M.P., Goorin A.M., Horowitz M., Meyer W.H., Belasco J., Baker A., Vala A., Shuster J. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. Clin. Orthop. 1991, 270:8-14.
6. Provisor A.J., Ettinger L.J., Nachman J.B., Krailo M.D., Makley J.T., Yunis E.J., Huvos A.G., Betcher D.L., Baum E.S., Kisker C.T., Miser J.S. Treatment of non-metastatic osteosarcoma of the extremity with pre-operative chemotherapy: a report from the Children's Cancer Group. J. Clin. Oncol. 1997, 15:76-84.
7. Man TK., Rao P.H., Lau C.C. Genomic and proteomic profiling of osteosarcoma. Bone Cancer: progression and therapeutic approaches 2010, 181-192. Academic Press. D. Heymann (Ed.).
8. Ando K., Mori K., Verrecchia F., Baud'huin M., Rédini F., Heymann D. Molecular alterations associated with osteosarcoma Development. Sarcoma 2012, 523432.
9. Heymann D., Rédini F. Targeted therapies for bone sarcomas. BoneKey Rep 2013, 2:378.
10. Ory B., Moriceau G., Rédini F., Heymann D. MTOR inhibitors (rapamycin and derivatives) and nitrogen-bisphosphonates: bi-functional compounds for the treatment of bone tumors. Curr. Med. Chem. 2007, 14:1381-1387.
11. Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 2010, 11:329-341.
12. Vadas O., Burke J.E., Zhang X., Berndt A., Williams R.L. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci. Signal 2011, 4. re2.
13. Janku F., Wheler J.J., Naing A., Stepanek V.M., Falchook G.S., Fu S., Garrido-Laguna I., Tsimberidou A.M., Piha-Paul S.A., Moulder S.L., Lee J.J., Luthra R., Hong D.S., Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 2012, 3:1566-1575.
14. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chène P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., García-Echeverría C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7:1851-1863.
15. Santiskulvong C., Konecny GE, Fekete M., Chen K.Y., Karam A., Muholland D., Eng C., Wu H., Song M., Dorigo O. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin. Cancer Res. 2011, 17:2373-2384.
16. Faber A.C., Li D., Song Y., Liang M.C., Yeap B.Y., Bronson R.T., Lifshits E., Chen Z., Maira S.M., García-Echeverría C., Wong K.K., Engelman J.A. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc. Natl. Acad. Sci. USA 2009, 106:19503-19508.
17. Bhatt A.P., Bhende P.M., Sin S.H., Roy D., Dittmer D.P., Damania B. Dual inhibition of PI3K and mTRO inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 2010, 115:4455-4463.
18. Manara M., Nicoletti G., Zambelli D., Ventura S., Guerzoni C., Landuzzi L., Lollini P.L., Maira S.M., García-Echeverría C., Mercuri M., Picci P., Scotlandi K. NVP-BEZ235 as a new therapeutic option for sarcoma. Clin. Cancer Res. 2010, 16:530-540.
19. Nanni P., Nicoletti G., Landuzzi L., Croci S., Murgo A., Palladini A., Antognoli A., Lanzano M.L., Stivani V., Grosso V., Maira S.M., García-Echeverría C., Scotlandi K., De Giovanni C., Lollini P.L. High metastatic efficiency of human sarcoma cells in Rag2/gc double knockout mice provides a powerful test system for antimetastatic targeted therapy. Eur. J. Cancer 2010, 46:659-668.
20. Klein B., Pals S., Masse R., Lafuma J., Morin M., Binart N., Jasmin J.R., Jasmin C. Studies of bone and soft-tissue tumours induced in rats with radioactive cerium chloride. Int. J. Cancer 1977, 20:112-119.
21. Kamijo K., Koshino T., Uesugi M., Nitto H., Saito T. Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. Cancer Lett. 2002, 188:213-219.
22. Joliat M.J., Umeda S., Lyons B.L., Lynes M.A., Shultz L.D. Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma. Vivo 2002, 16:223-228.
23. Moriceau G., Ory B., Mitrofan L., Riganti C., Blanchard F., Brion R., Charrier C., Battaglia S., Pilet P., Denis M.G., Shultz L.D., Mönkkönen J., Rédini F., Heymann D. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res. 2010, 70:10329-10339.
24. Lamoureux F., Richard P., Wittrant Y., Battaglia S., Pilet P., Trichet V., Blanchard F., Gouin F., Pitard B., Heymann D., Redini F. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 2007, 67:7308-7318.
25. Zhang Y.X., van Oosterwijk J.G., Sicinska E., Moss S., Remillard S.P., van Wezel T., Bühnemann C., Hassan A.B., Demetri G.D., Bovée J.W., Wagner A.J. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin. Cancer Res. 2013, 19:3796-3807.
26. David E., Blanchard F., Heymann M.F., De Pinieux G., Gouin F., Rédini F., Heymann D. The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets. Sarcoma 2011, 932451.
27. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
28. Fallica B., Maffei J.S., Villa S., Makin G., Zaman M. Alteration of cellular behavior and response to PI3K pathway inhibition by culture in 3D collagen gels. PLoS One 2012, 7:e48024.
29. Zhao G., Cai C., Yang T., Qiu X., Liao B., Li W., Ji Z., Zhao J., Zhao H., Guo M., Ma Q., Xiao C., Fan Q., Ma B. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 2013, 8:e53906.
30. Wang K., Zhuang Y., Liu C., Li Y. Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling. Arch. Biochem. Biophys. 2012, 526:38-43.
31. Tsubaki M., Satou T., Itoh T., Imano M., Ogaki M., Yanae M., Nishida S. Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Toxicol. Appl. Pharmacol. 2012, 259:402-410.
32. Fukaya Y., Ishiguro N., Senga T., Ichigotani Y., Sohara Y., Tsutsui M., Shioura T., Iwamoto T., Hamaguchi M. A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8. Oncol. Rep. 2005, 14:847-852.
33. Kontzoglou K., Palla V., Karaolanis G., Karaiskos I., Alexiou I., Pateras I., Konstantoudakis K., Stamatakos M. Correlation betweenKi67and breast cancer prognosis. Oncology 2013, 84(84):219-225.
34. Guinebretière J.M., Sabourin J.C. Ki-67, marker of proliferation. Ann. Pathol. 1997, 17:25-30.
35. Zheng C., Qiu Y., Zeng Q., Zhang Y., Lu D., Yang D., Feng J., Yan X. EndothelialCD146is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization. Int. J. Biochem. Cell Biol. 2009, 41:2163-2172.
36. Jiang T., Zhuang J., Duan H., Luo Y., Zeng Q., Fan K., Yan H., Lu D., Ye Z., Hao J., Feng J., Yang D., Yan X. CD146is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 2012, 120:2330-2339.
37. Schnell C.R., Stauffer F., Allegrini P.R., O'Reilly T., McSheehy P.M., Dartois C., Stumm M., Cozens R., Littlewood-Evans A., García-Echeverría C., Maira S.M. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 2008, 68:6598-6607.
38. Hadji P., Coleman R., Gnant M. Boneeffects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Crit. Rev. Oncol. Hematol. 2013, 87:101-111.
39. Martin S.K., Fittre S., Bon L.F., Drew J.J., Gronthos S., Shepherd P.R., Zannettino A.C. NVP-235, a dual pan class I PI3K and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J. Bone Miner. Res. 2010, 25:2126-2137.
40. Devlin R.D., Du Z., Pereira R.C., Kimble R.B., Economides A.N., Jorgetti V., Canalis E. Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 2003, 144:1972-1978.
41. Canalis E., Brunet L.J., Parker K., Zanotti S. Conditional inactivation ofnogginin the postnatal skeleton causes osteopenia. Endocrinology 2012, 153:1616-1626.